This segment frames the current first-line treatment landscape for EGFR-mutant metastatic non–small cell lung cancer and how it has evolved over two decades.
This episode explores how overall survival data, toxicity profiles, and guideline categorizations inform frontline decision-making.
Experts weigh NCCN category 1 value and show how serial brain MRIs shape EGFR lung cancer first-line treatment decisions.
Experts compare EGFR lung cancer first-line combos, weighing chemo vs amivantamab-lazurtnib toxicity, quality of life, and patient-centered choice.
Experts weigh combo therapy for EGFR L858R/TP53 lung cancer with brain mets, balancing radiation and systemic options to cut visits.
Experts weigh EGFR L858R/TP53 stage IV NSCLC options, combo regimens and brain-met strategies to boost control, ease visits.
Learn practical systems for managing EGFR therapy side effects, triage tips, and what’s next for resistance in metastatic NSCLC.
